Close Menu

NEW YORK – QED Therapeutics and Helsinn Group entered into a $2 billion licensing agreement on Wednesday to codevelop and commercialize QED's FGFR1-3 inhibitor, infigratinib, in oncology in the US.

Under the terms of the deal, QED, a subsidiary of BridgeBio, will be eligible to receive up to $2 billion in upfront, regulatory, milestone, and royalty payments related to infigratinib. If the drug achieves US regulatory approval, QED and Helsinn will co-commercialize it in oncology indications in the US and will evenly split profits and losses.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.